Forskning
Udskriv Udskriv
Switch language
Hvidovre Hospital - en del af Københavns Universitetshospital
Udgivet

Mechanisms of Hepatitis C Virus Escape from Vaccine-Relevant Neutralizing Antibodies

Publikation: Bidrag til tidsskriftReviewpeer review

DOI

  1. SARS-CoV-2 Production in a Scalable High Cell Density Bioreactor

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  1. Hepatitis C virus envelope protein dynamics and the link to hypervariable region 1

    Publikation: Bidrag til tidsskriftReviewpeer review

  2. Global and local envelope protein dynamics of hepatitis C virus determine broad antibody sensitivity

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

Vis graf over relationer

Hepatitis C virus (HCV) is a major causative agent of acute and chronic hepatitis. It is estimated that 400,000 people die every year from chronic HCV infection, mostly from severe liver-related diseases such as cirrhosis and liver cancer. Although HCV was discovered more than 30 years ago, an efficient prophylactic vaccine is still missing. The HCV glycoprotein complex, E1/E2, is the principal target of neutralizing antibodies (NAbs) and, thus, is an attractive antigen for B-cell vaccine design. However, the high genetic variability of the virus necessitates the identification of conserved epitopes. Moreover, the high intrinsic mutational capacity of HCV allows the virus to continually escape broadly NAbs (bNAbs), which is likely to cause issues with vaccine-resistant variants. Several studies have assessed the barrier-to-resistance of vaccine-relevant bNAbs in vivo and in vitro. Interestingly, recent studies have suggested that escape substitutions can confer antibody resistance not only by direct modification of the epitope but indirectly through allosteric effects, which can be grouped based on the breadth of these effects on antibody susceptibility. In this review, we summarize the current understanding of HCV-specific NAbs, with a special focus on vaccine-relevant bNAbs and their targets. We highlight antibody escape studies pointing out the different methodologies and the escape mutations identified thus far. Finally, we analyze the antibody escape mechanisms of envelope protein escape substitutions and polymorphisms according to the most recent evidence in the HCV field. The accumulated knowledge in identifying bNAb epitopes as well as assessing barriers to resistance and elucidating relevant escape mechanisms may prove critical in the successful development of an HCV B-cell vaccine.

OriginalsprogEngelsk
Artikelnummer291
TidsskriftVaccines
Vol/bind9
Udgave nummer3
Sider (fra-til)1-19
Antal sider19
ISSN2076-393X
DOI
StatusUdgivet - 20 mar. 2021

Bibliografisk note

Funding Information:
This manuscript was supported by a postdoc grant from the Lundbeck Foundation (R303-2018-3396 To RVM), a Ph.D. stipend from the Candy Foundation (CHO), an Experiment grant from the Lundbeck Foundation (grant number: R324-2019-1375 to JP) and a Lundbeck Foundation Fellowship (grant number: R335-2019-2052 to JP).

ID: 64730722